Will psychedelics ever live up to their hype? How small studies and weak blinding limit proof of mental health benefits

Psychedelics are widely discussed as mental health treatments, but National Geographic reports that the current evidence has not yet proven broad benefits and still faces major research limits. The article highlights three key problems: psychedelic studies are often unusually small and expensive to run, psychedelic trials are hard to keep truly double-blind because participants can figure out they took an active drug, and addiction or abuse risk is not always addressed with the same seriousness as clinical efficacy. It also notes public and policy momentum, including state-level legalization pathways and FDA review dynamics, while pointing to regulatory scrutiny such as concerns raised around MDMA for PTSD and the need for larger, higher-standard trials to avoid premature conclusions.